Puma Biotechnology | PBYI - 应收帐款人





应收帐款人 更改 日
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
Alnylam Pharmaceuticals USD 883.96M 106.39M 2026-03
Amgen USD 9.14B 432M 2026-03
Biogen USD 1.79B 76.6M 2026-03
BioMarin Pharmaceutical USD 903.91M 4.3M 2026-03
Daiichi Sankyo JPY 695.95B 79.1B 2025-12
Esperion Therapeutics USD 140.19M 21.21M 2025-12
Exelixis USD 286.92M 24.38M 2025-12
Gilead Sciences USD 4.91B 182M 2025-12
Glaxosmithkline GBP 10.45B 707.81M 2025-12
Incyte USD 1.05B 27.09M 2026-03
MacroGenics USD 13.37M 55.86M 2025-12
Moderna USD 71M 113M 2026-03
Novartis USD 9.6B 2.69B 2026-03
Pfizer USD 15.84B 2.27B 2025-12
PTC Therapeutics USD 181.62M 21.45M 2025-12
Puma Biotechnology USD 28.1M 3.52M 2024-06
Regeneron Pharmaceuticals USD 5.73B 10.1M 2026-03
Roche Holding CHF 11.9B 460M 2025-12
Sangamo BioSciences USD 581K 110K 2024-06
Sarepta Therapeutics USD 398.23M 2.49M 2025-12
Takeda JPY 757.92B 55.68B 2025-12
TG Therapeutics USD 265.38M 33.86M 2025-09
Ultragenyx Pharmaceutical USD 158M 45.46M 2025-12
Vanda Pharmaceuticals USD 47.1M 4.35M 2024-12
Vertex Pharmaceuticals USD 2B 56.7M 2026-03